Repaglinide/Clopidogrel Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Clopidogrel may slow down how quickly your liver processes repaglinide.
What might happen:
The amount of repaglinide in your blood may increase and it may lower your blood sugar too much.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your doctor may want to change one of your medicines or adjust the dose of your repaglinide. You may need to check your blood sugar more often, especially when you start taking these medicines together. Let your doctor know if you have any symptoms of low blood sugar, such as sweating, rapid heartbeat, dizziness, or weakness.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyronen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 2014 Oct; 96(4):498-507.
- 2.Health Canada. Gluconorm (repaglinide) - New Contraindication for Concomitant Use with Clopidogrel. accessed at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/54454a-e ng.php July 31, 2015.
- 3.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 4.Plavix (clopidogrel bisulfate) US prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership September, 2022.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.